Inhibition by somatostatin of the release of growth hormone induced by lysine-vasopressin in normal subjects.
The effect of somatostatin (SRIH) on the release of growth hormone (GH) induced by lysine-vasopressin (LVP) was studied in six normal subjects. They were injected intravenously with 0.06 I. U./kg of LVP alone or in combination with SRIH (an intravenous bolus of 100 micrograms 10 minutes before LVP injection, followed by the constant infusion of 500 micrograms over 90 minutes). LVP strikingly increased serum concentrations of GH; this response was significantly reduced by the treatment with SRIH. This finding provides evidence that the effect of LVP on serum GH levels is sensitive to the inhibition by SRIH; it is proposed that the stimulating action of LVP on GH secretion might be mediated by the inhibition of endogenous SRIH.
Chiodera
P
P
Coiro
V
V
D000328:Adult; D005260:Female; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism*; D006801:Humans; D008236:Lypressin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D008297:Male; D013004:Somatostatin / Q000494:pharmacology*
D008236:Lypressin; D013004:Somatostatin; D013006:Growth Hormone